KLRK1 and glioblastoma: For instance, in conditions like acute myeloid leukemia, breast cancer, and glioblastoma, CSCs have been observed to downregulate the expression of NK cell-activating ligands (e.g., NKG2D ligands) and release ligands that inhibit NK cell recognition and killing, such as MICA, MICB, and ULBP1-6, enabling successful immune escape.